
Amyris, Inc. – NASDAQ:AMRS
Amyris stock price today
Amyris stock price monthly change
Amyris stock price quarterly change
Amyris stock price yearly change
Amyris key metrics
Market Cap | N/A |
Enterprise value | 1.28B |
P/E | -0.66 |
EV/Sales | 4.76 |
EV/EBITDA | -2.68 |
Price/Sales | 1.36 |
Price/Book | -0.76 |
PEG ratio | N/A |
EPS | -1.83 |
Revenue | 268.22M |
EBITDA | -521.74M |
Income | -628.26M |
Revenue Q/Q | -2.81% |
Revenue Y/Y | 20.45% |
Profit margin | -195.86% |
Oper. margin | -219.63% |
Gross margin | 4.14% |
EBIT margin | -219.63% |
EBITDA margin | -194.52% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAmyris stock price history
Amyris stock forecast
Amyris financial statements
Jun 2022 | 65.20M | -108.54M | -166.47% |
---|---|---|---|
Sep 2022 | 71.12M | -167.27M | -235.17% |
Dec 2022 | 75.80M | -150.66M | -198.76% |
Mar 2023 | 56.08M | -201.77M | -359.78% |
Jun 2022 | 789440000 | 1.03B | 130.86% |
---|---|---|---|
Sep 2022 | 754060000 | 1.15B | 153.68% |
Dec 2022 | 824932000 | 1.29B | 156.7% |
Mar 2023 | 679679000 | 1.32B | 195.35% |
Jun 2022 | -147.04M | -41.93M | 3.26M |
---|---|---|---|
Sep 2022 | -133.53M | -30.08M | 81.28M |
Dec 2022 | -92.87M | -4.39M | 142.90M |
Mar 2023 | -90.00M | -4.81M | 41.61M |
Amyris alternative data
Amyris
4 Aug 2024 | 22 |
---|---|
11 Aug 2024 | 16 |
18 Aug 2024 | 18 |
25 Aug 2024 | 19 |
1 Sep 2024 | 17 |
8 Sep 2024 | 19 |
15 Sep 2024 | 17 |
22 Sep 2024 | 13 |
29 Sep 2024 | 14 |
6 Oct 2024 | 13 |
13 Oct 2024 | 10 |
20 Oct 2024 | 11 |
27 Oct 2024 | 11 |
3 Nov 2024 | 14 |
10 Nov 2024 | 15 |
17 Nov 2024 | 14 |
24 Nov 2024 | 14 |
1 Dec 2024 | 14 |
8 Dec 2024 | 16 |
15 Dec 2024 | 22 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
Aug 2023 | 5 |
---|---|
Sep 2023 | 5 |
Oct 2023 | 13 |
Nov 2023 | 16 |
Dec 2023 | 18 |
Jan 2024 | 22 |
Feb 2024 | 21 |
Apr 2024 | 15 |
May 2024 | 13 |
Jun 2024 | 12 |
Jul 2024 | 8 |
Dec 2024 | 12 |
Jan 2025 | 9 |
Feb 2025 | 19 |
May 2025 | 18 |
Jul 2025 | 18 |
Aug 2025 | 19 |
Aug 2023 | 1,598 |
---|---|
Sep 2023 | 1,598 |
Oct 2023 | 1,598 |
Nov 2023 | 1,598 |
Dec 2023 | 1,598 |
Jan 2024 | 1,598 |
Feb 2024 | 1,598 |
Mar 2024 | 1,598 |
Apr 2024 | 1,598 |
May 2024 | 1,598 |
Jun 2024 | 1,598 |
Jul 2024 | 1,598 |
Amyris other data
Period | Buy | Sel |
---|---|---|
Jul 2022 | 0 | 55576 |
Aug 2022 | 17155 | 0 |
Sep 2022 | 0 | 3788592 |
Apr 2023 | 0 | 231368 |
Jun 2023 | 0 | 20999 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | KIEFTENBELD HERMANUS officer: CHIEF FI.. | Common Stock | 17,499 | $0.95 | $16,624 | ||
Sale | KIEFTENBELD HERMANUS officer: CHIEF FI.. | Common Stock | 3,500 | $0.95 | $3,325 | ||
Sale | ALVAREZ EDUARDO officer: CHIEF OP.. | Common Stock | 231,368 | $1.23 | $284,351 | ||
Option | ALVAREZ EDUARDO officer: CHIEF OP.. | Common Stock | 492,000 | N/A | N/A | ||
Option | ALVAREZ EDUARDO officer: CHIEF OP.. | Performance-based Restricted Stock Units | 492,000 | N/A | N/A | ||
Sale | KUNG FRANK director | Common Stock | 36,488 | $3.5 | $127,708 | ||
Sale | KUNG FRANK director | Common Stock | 72,972 | $3.6 | $262,699 | ||
Sale | KUNG FRANK director | Common Stock | 327,028 | $3.6 | $1,177,301 | ||
Sale | KUNG FRANK director | Common Stock | 197,148 | $3.8 | $749,162 | ||
Sale | KUNG FRANK director | Common Stock | 883,528 | $3.8 | $3,357,406 |
Patent |
---|
Application Filling date: 31 Jul 2020 Issue date: 8 Sep 2022 |
Application Filling date: 9 Mar 2022 Issue date: 11 Aug 2022 |
Grant Utility: Methods for genomic integration Filling date: 11 Mar 2020 Issue date: 19 Jul 2022 |
Grant Filling date: 12 Sep 2018 Issue date: 19 Jul 2022 |
Application Filling date: 3 Nov 2021 Issue date: 19 May 2022 |
Application Filling date: 13 Mar 2020 Issue date: 28 Apr 2022 |
Grant Filling date: 27 Jun 2019 Issue date: 26 Apr 2022 |
Application Filling date: 23 Jan 2020 Issue date: 7 Apr 2022 |
Grant Utility: Compositions and methods for genomic integration of nucleic acids into exogenous landing pads Filling date: 18 May 2017 Issue date: 5 Apr 2022 |
Grant Filling date: 2 Jan 2020 Issue date: 25 Jan 2022 |
Quarter | Transcript |
---|---|
Q1 2023 9 May 2023 | Q1 2023 Earnings Call Transcript |
Q4 2022 16 Mar 2023 | Q4 2022 Earnings Call Transcript |
Q3 2022 8 Nov 2022 | Q3 2022 Earnings Call Transcript |
Q2 2022 9 Aug 2022 | Q2 2022 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. John G. Melo (1966) Pres, Chief Executive Officer & Director | $1,340,000 |
Mr. Eduardo Alvarez (1964) Chief Operating Officer | $959,760 |
Mr. Hermanus Kieftenbeld (1966) Chief Financial Officer & Chief Admin. Officer | $817,840 |
Ms. Nicole Kelsey (1967) Gen. Counsel & Sec. | $541,530 |
Amyris: CEO's Exit Has Negative Implications
Amyris: Company Separates From Long-Standing CEO Amid Ongoing Restructuring Efforts - Sell
Amyris: Sub-Scale With High Fixed Costs And Limited Growth
Amyris: Darkest Before The Dawn
Amyris: Show Us The Money
Amyris: No Relief
From Spending Cash To Fermenting Money: Amyris Is Fit To Profit From High ROI Plants And Innovative Marketing
Amyris: Consumer Business Cost Breakdown
Ginkgo Bioworks: Business Model Uncertainty
-
What's the price of Amyris stock today?
One share of Amyris stock can currently be purchased for approximately $0.05.
-
When is Amyris's next earnings date?
Unfortunately, Amyris's (AMRS) next earnings date is currently unknown.
-
Does Amyris pay dividends?
No, Amyris does not pay dividends.
-
What is Amyris's stock symbol?
Amyris, Inc. is traded on the NASDAQ under the ticker symbol "AMRS".
-
What is Amyris's primary industry?
Company operates in the Basic Materials sector and Chemicals - Specialty industry.
-
How do i buy shares of Amyris?
Shares of Amyris can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Amyris's key executives?
Amyris's management team includes the following people:
- Mr. John G. Melo Pres, Chief Executive Officer & Director(age: 59, pay: $1,340,000)
- Mr. Eduardo Alvarez Chief Operating Officer(age: 61, pay: $959,760)
- Mr. Hermanus Kieftenbeld Chief Financial Officer & Chief Admin. Officer(age: 59, pay: $817,840)
- Ms. Nicole Kelsey Gen. Counsel & Sec.(age: 58, pay: $541,530)
-
How many employees does Amyris have?
As Jul 2024, Amyris employs 1,598 workers.
-
When Amyris went public?
Amyris, Inc. is publicly traded company for more then 14 years since IPO on 28 Sep 2010.
-
What is Amyris's official website?
The official website for Amyris is amyris.com.
-
Where are Amyris's headquarters?
Amyris is headquartered at 5885 Hollis Street, EmeryVille, CA.
-
How can i contact Amyris?
Amyris's mailing address is 5885 Hollis Street, EmeryVille, CA and company can be reached via phone at +51 04500761.
Amyris company profile:

Amyris, Inc.
amyris.comNASDAQ
1,598
Chemicals - Specialty
Basic Materials
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
EmeryVille, CA 94608
CIK: 0001365916
ISIN: US03236M2008
CUSIP: 03236M200